首页> 外文期刊>Acta Cardiologica >Meta-analysis of drug-eluting versus bare metal stents in patients with indications for oral anticoagulation undergoing coronary stenting
【24h】

Meta-analysis of drug-eluting versus bare metal stents in patients with indications for oral anticoagulation undergoing coronary stenting

机译:药物洗脱支架与裸金属支架的Meta分析对有冠状动脉支架置入术患者口服抗凝的适应症

获取原文
获取原文并翻译 | 示例
           

摘要

Background Current expert consensus recommends the use of bare metal stent (BMS) for patients with an indication for oral anticoagulation (OAC) undergoing coronary stenting. The use of drug-eluting stents (DES) should be limited. However, there is a lack of evidence to support these recommendations. We performed a meta-analysis to compare the effi cacy and safety of DES to BMS in these patients. Methods We searched PubMed, Embase, the Cochrane library, and relevant journals. Studies comparing the effi cacy and safety of DES to BMS in patients with an indication for OAC undergoing coronary stenting were included. End points included major adverse cardiac events (MACE), death, bleeding complications, and stroke. The outcome assessments were measured by hazard ratio (HR) and its 95% confi dence interval. Results We yielded 453 studies by primary searching. According to the inclusion criteria, four studies enrolling 1,522 patients were fi nally included. A pooled estimate of HR for MACE, all-cause mortality, myocardial infarction, and bleeding complications showed no signifi cant diff erences between patients treated with DES and BMS. The risk of target vessel revascularization (TVR) was signifi cantly decreased in the DES implanted patients in comparison with patients with a BMS implantation. Conclusion For patients with an indication for OAC undergoing coronary stenting, DES might a DES can be as safely used as a BMS, and is superior in reducing the risk of TVR.
机译:背景技术当前专家共识建议对有冠状动脉支架置入术的口服抗凝(OAC)适应症的患者使用裸金属支架(BMS)。应该限制​​药物洗脱支架(DES)的使用。但是,缺乏支持这些建议的证据。我们进行了荟萃分析,比较了DES与BMS在这些患者中的疗效和安全性。方法我们搜索了PubMed,Embase,Cochrane库和相关期刊。包括比较DES与BMS对有OAC冠状动脉支架置入指征的患者的疗效和安全性的研究。终点包括主要的不良心脏事件(MACE),死亡,出血并发症和中风。结果评估通过危险比(HR)及其置信区间的95%进行衡量。结果我们通过初步搜索获得了453项研究。根据纳入标准,最终纳入了纳入1,522名患者的四项研究。对MACE,全因死亡率,心肌梗塞和出血并发症的HR汇总估算显示,DES和BMS治疗的患者之间无显着差异。与BMS植入患者相比,DES植入患者的靶血管血运重建(TVR)风险显着降低。结论对于有OAC冠状动脉支架置入指征的患者,DES可以像BMS一样安全地使用,并且在降低TVR风险方面具有优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号